{"contentid": 488496, "importid": NaN, "name": "Protalix shares plummet by 44% on CRL news", "introduction": "Shares in Protalix BioTherapeutics closed 44% lower on Wednesday after the firm and its partner Chiesi Farmaceutici announced receipt of a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) seeking accelerated approval of pegunigalsidase alfa (PRX\u00e2\u0080\u0093102) for Fabry disease.", "content": "<p>Shares in Protalix BioTherapeutics (TASE: PLX) closed 44% lower on Wednesday after the firm and its partner Chiesi Farmaceutici announced receipt of a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) seeking accelerated approval of pegunigalsidase alfa (PRX&ndash;102) for Fabry disease.</p>\n<p>The Israeli pharma company stressed that the CRL did not report any concerns relating to the potential safety or efficacy of PRX&ndash;102 in the submitted data package.</p>\n<p>In the CRL, the FDA noted that an inspection of Protalix' manufacturing facility in Carmiel, Israel, including its subsequent assessment of any related findings, is required before the agency can approve the BLA.</p>\n<p><span class=\"pullQuote\">\"Protalix remains confident that it will be able to work with the FDA to resolve these issues and provide a new, alternative drug to Fabry patients\"</span>Due to travel restrictions, the FDA was unable to conduct the required inspection during the review cycle.</p>\n<p>A statement from Protalix said that the FDA will continue to monitor the public health situation as well as travel restrictions, and is actively working to define an approach for scheduling outstanding inspections.</p>\n<p>The statement adds: &ldquo;With respect to the third-party facility in Europe at which fill and finish processes are performed for PRX-102, due to COVID&ndash;19, the FDA reviewed records under Section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act in lieu of a pre-licensing inspection. In the CRL, the FDA stated that it will communicate remaining issues to the facility in order to seek prompt resolution of any pending items.&rdquo;</p>\n<p>Meanwhile, Sanofi&rsquo;s (Euronext: SAN) Fabrazyme (agalsidase beta) has recently been converted to full approval by the FDA, something that the agency has noted that Protalix will have to address in any potential resubmission seeking accelerated approval of PRX 102.</p>\n<p>Protalix has compared its drug with the Sanofi competitor in an attempt to show that PRX-102 can provide a new option in Fabry disease.</p>\n<p>The company&rsquo;s statement adds: &ldquo;Protalix intends to work collaboratively with the agency to identify the most expeditious pathway to approval, including accelerated approval. Protalix remains confident that it will be able to work with the FDA to resolve these issues and provide a new, alternative drug to Fabry patients. Protalix intends to request a Type-A meeting with the FDA, and will provide further updates on next steps after the meeting.&rdquo;</p>", "date": "2021-04-29 13:01:00", "meta_title": NaN, "meta_keywords": "Protalix, drug, approval, Fabry, shares, accelerated, Food, seeking, disease, provide, news, plummet, partner, Chiesi, Farmaceutici, firm, Wednesday, close", "meta_description": "Shares in Protalix BioTherapeutics closed 44% lower on Wednesday after the firm and its partner Chiesi Farmaceutici announced receipt of a Complete Response Let", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-29 12:56:10", "updated": "2021-04-29 13:53:40", "access": NaN, "url": "https://www.thepharmaletter.com/article/protalix-shares-plummet-by-44-on-crl-news", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "protalix_large.jpg", "image2id": "protalix-small.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": "Fabry disease, US Food and Drug Administration", "sector_tag": "Biotechnology", "therapy area_tag": "Rare diseases", "topic_tag": "Focus On, Regulation, US FDA", "geography_tag": "Israel, Italy, USA", "company_tag": "Chiesi Farmaceutici, Protalix BioTherapeutics", "drug_tag": "pegunigalsidase alfa, PRX-102", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-29 13:01:00"}